From Psilocybin to MDMA: Psychedelic Catalyzation of Therapeutic Process

With the recent approval by the FDA of Phase 3 research on MDMA to treat PTSD, there is a careful reconsideration of the use of psychedelics to provide relief for treatment resistant conditions. During this presentation and discussion, Bruce Sewick (MA, LCPC, CADC, RDDP) will discuss information learned from early research such as The Good Friday Experiment and how current research provides a scientific basis for rescheduling of some psychedelics for supervised therapeutic use in a clinical setting.